Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Head Neck. 2013 Dec;35(12):E372-5. doi: 10.1002/hed.23307. Epub 2013 Jun 14.
Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option.
A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab.
The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression.
Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.
唾液腺癌（SDC）是一种预后不良的罕见恶性肿瘤。SDC 中过表达人类表皮生长因子受体-2（Her-2/neu），因此 HER-2/neu 靶向治疗可能是一种选择。
一名 72 岁男性因腮腺肿胀和颈部淋巴结病就诊。他接受了腮腺切除术、改良根治性颈淋巴结清扫术和术后顺铂化疗放疗。一年后，他的对侧颈部出现转移性疾病，经手术治疗并伴有右侧腋窝淋巴结病。他接受了两个部位的放射治疗，同时接受卡铂治疗。两年后，他接受了肺转移瘤切除术。然后，他的腋窝和纵隔淋巴结出现进展，接受了 5 个周期的多西紫杉醇和曲妥珠单抗治疗，随后进行维持曲妥珠单抗治疗。
患者有部分缓解，停药 9 个月后的复查显示无进展。
曲妥珠单抗为基础的治疗是 SDC 患者的一种潜在治疗选择。
